OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Manfred Windisch

4 Projects | 1 Researchers | $5,383,336 Invested

2024

NSC-Therapeutics GmbH

Manfred Windisch, PhD

A 2-Part, phase 2a, Multi-Center, randomised, double blinded, placebo controlled clinical trial investigating safety and tolerability, PK and exploratory efficacy of the M1 selective rigid, orthosteric M1 agonist NSC001 in patients suffering from mild to moderate Alzheimer’s Disease

  • Funding Amount: $4,998,336
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Active

2007

JSW Lifesciences GmbH

Manfred Windisch, PhD

ß-synuclein derived peptides for the treatment of neurodegenerative diseases

  • Funding Amount: $120,000
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Status: Closed

2001

JSW Lifesciences GmbH

Manfred Windisch, PhD

Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory Beta-Synuclein derived peptides

  • Funding Amount: $260,000
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Status: Closed

2001

JSW Lifesciences GmbH

Manfred Windisch, PhD

5th International Conference on Aging and Dementia - Current and Future Concepts

  • Funding Amount: $5,000
  • Organization Type: Biotechnology/For Profit
  • Program: Conferences/Other
  • Status: Closed